Acute myeloid leukemia (AML) is frequently associated with genomic mutations in the gene of DNA-methyltransferase 3A (DNMT3A). Recently discovered epimutations within the same gene can mimic these mutations and are indicative for the survival of AML patients. Cygenia provides an analysis of the DNMT3A epimutation for physicians and scientists to gain better insight into disease development.
Area of application
These assays are developed for physicians and scientists. If the doctor in charge wants to consider these new methods to support diagnosis of individual patients, this approach may be valuable – however, it has to be noted that the validity of this new method still requires further research. So far, this service is for research use only.
Jost E. et al. Epimutations Mimic Genomic Mutations of DNMT3A in Acute Myeloid Leukemia. Leukemia, 2014.
Patent application: 2013; EP 13167411.1